DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Divalproex Sodium is a drug marketed by Ajanta Pharma Ltd, Dr Reddys Labs Ltd, Mylan, Teva Pharms Usa, Zydus Pharms Usa Inc, Actavis Labs Fl Inc, Anchen Pharms, Apotex, Aurobindo Pharma Ltd, Celltrion, Invatech, Lupin, Orchid Hlthcare, Prinston Inc, Sun Pharm Inds, Teva, Unichem Labs Ltd, Upsher Smith Labs, Amneal Pharms, Amta, Cosette, Impax Labs, Lupin Ltd, Reddys, and Wockhardt. and is included in thirty-four NDAs.
The generic ingredient in DIVALPROEX SODIUM is divalproex sodium. There are eighteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
A generic version of DIVALPROEX SODIUM was approved as divalproex sodium by APOTEX on July 29th, 2008.
Summary for DIVALPROEX SODIUM
|Finished Product Suppliers / Packagers:||39|
|Raw Ingredient (Bulk) Api Vendors:||57|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for DIVALPROEX SODIUM|
|Drug Sales Revenues:||Drug sales revenues for DIVALPROEX SODIUM|
|What excipients (inactive ingredients) are in DIVALPROEX SODIUM?||DIVALPROEX SODIUM excipients list|
|DailyMed Link:||DIVALPROEX SODIUM at DailyMed|
Recent Clinical Trials for DIVALPROEX SODIUM
Identify potential brand extensions & 505(b)(2) entrants
|Universidad Autonoma de San Luis Potosí||Phase 3|
|Puma Biotechnology, Inc.||Phase 1/Phase 2|
|Virginia Commonwealth University||Phase 1/Phase 2|
Pharmacology for DIVALPROEX SODIUM
|Drug Class||Anti-epileptic Agent |
|Physiological Effect||Decreased Central Nervous System Disorganized Electrical Activity |